Loading…
ANADIN EXTRA SOLUBLE is a brand name for Caffeine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For the treatment of mild to moderate pain including headache, migraine, neuralgia, toothache, sore throat, period pains, symptomatic relief of sprains, strains, rheumatic pain, sciatica, lumbago, fibrositis, muscular aches and pains, joint swelling and stiffness, influenza, feverishness and feverish colds.
Verbatim from this product's MHRA label. Tap a section to expand.
Adults, the elderly and young persons aged 16 and over: 2 tablets every 4 hours to a maximum of 8 tablets in 24 hours. g. for Kawasaki’s disease). For migraine indication: use of this medicine is not recommended for children and adolescents (under 18 years of age).
73m2). Aspirin is known to cause sodium and water retention which may exacerbate hypertension, congestive heart failure and renal impairment (see Contraindications, Warnings and Precautions).
Hepatic Impairment:
Contraindicated in patients with hepatic failure (see Contraindications, Warnings and Precautions).
The following convention has been utilised for the classification of the frequency of adverse reactions: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1000), very rare (<1/10,000), not known (cannot be estimated from available data).
Adverse reactions from historical clinical trial data are both infrequent and from small patient exposure. Accordingly, events reported from extensive post- marketing experience at therapeutic/labeled dose and considered attributable are tabulated below by MedDRA System Organ Class.
As these reactions are reported voluntarily from a population of uncertain size, the frequency of these reactions is not known but likely to be rare or very rare (<1/1000). Adverse events are more likely to occur with increasing dose and duration of use.
MedDRA SOC Adverse Reaction Frequency Aspirin Blood and lymphatic system disorders Prolonged bleeding time, thrombocytopenia, ecchymosis. g. anaphylaxis, angioedema, bronchospasm, urticaria, skin reactions and rhinitis). Not known Respiratory, thoracic and mediastinal disorders Aspirin-exacerbated respiratory disease Very rare Metabolism and Nutrition disorders Sodium and fluid retention.
Not known Ear and labyrinth disorders Temporary hearing loss, tinnitus. Not known Gastrointestinal disorders Gastrointestinal haemorrhage, gastrointestinal ulceration, vomiting, gastritis, nausea, and dyspepsia. Not known Hepatobiliary disorders Reye’s syndrome (see Warnings and Precautions).
Elevation in aminotransferase levels. Not known Renal and urinary disorders Renal dysfunction, increased blood uric acid levels. Not known Paracetamol Blood and lymphatic system disorders Thrombocytopenia. Very rare Immune system disorders Anaphylaxis Cutaneous hypersensitivity reactions including, among others, skin rashes, angioedema, Stevens–Johnson syndrome and Toxic Epidermal Necrolysis.
Serious hypersensitivity reactions or anaphylaxis can occur, bronchospasm may be precipitated in patients suffering from or with a previous history of asthma, allergic disease or nasal polyps. Aspirin should be used with caution in patients with uncontrolled hypertension (in whom target blood pressure has not been achieved), impaired renal or hepatic function, or in patients who are dehydrated or suffering from diabetes mellitus.
The overall benefit-risk should be considered in patients diagnosed with hepatic or renal impairment before useThe hazards of overdose are greater in those with non-cirrhotic alcoholic liver disease. Contains paracetamol. Do not use with any other paracetamol containing products.
The concomitant use with other products containing paracetamol may lead to an overdose. Do not take if you have a stomach ulcer. Do not take more medicine than the label tells you to. Paracetamol overdose may cause liver failure which may require liver transplant or lead to death.
Talk to your doctor at once if you take too much of this medicine, even if you feel well. This is because too much paracetamol can cause delayed, serious liver damage. Underlying liver disease increases the risk of paracetamol- related liver damage.
The overall benefit-risk should be considered in patients diagnosed with hepatic or renal impairment before use. If you do not get better, talk to your doctor. There is a possible association between aspirin and Reye’s syndrome when given to children, especially during or immediately after a viral illness.
Reye’s syndrome is a very rare disease, which affects the brain and liver, and can be fatal. g. Kawasaki’s disease). Aspirin decreases platelet adhesiveness and increases bleeding time. Haematological and haemorrhagic effects can occur and may be severe.
Patients should report any unusual bleeding symptoms to their physician. In patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, aspirin may induce haemolysis or haemolytic anaemia. Factors that may increase the risk of haemolysis are high dosage, fever, or acute infections.
This combination is contraindicated in the following conditions: - Hypersensitivity to the active ingredients or to any other excipients. - Patients in whom asthma, bronchospasm, angioedema, urticaria, or acute rhinitis are precipitated by aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).
- Peptic ulceration and those with a history of peptic ulceration; - History of upper gastrointestinal bleeding or perforation, related to previous NSAID therapy. 73m2). - Hepatic failure. - Third trimester of pregnancy - children under 16 years and when breast feeding because of possible risk of Reye's Syndrome.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Caffeine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Very rare Respiratory, thoracic and mediastinal disorders Bronchospasm in patients sensitive to aspirin and other NSAIDs. Very rare Hepatobiliary disorders Hepatic dysfunction. Very rare Metabolism and Nutrition High anion gap metabolic acidosis Not known Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Gastrointestinal bleeding, ulceration or perforation, which can be fatal, have been reported with all NSAIDs and may occur at any time during treatment, with or without warning symptoms or a previous history of serious GI events. These effects generally have more serious consequences in the elderly (see Interactions) Cases of hepatic dysfunction/failure have been reported in patients with depleted glutathione levels, such as those who are severely malnourished, anorexic, have a low body mass index or are chronic heavy users of alcohol or have sepsis.
In patients with glutathione depleted states, the use of paracetamol may increase the risk of metabolic acidosis. Aspirin can reduce uric acid excretions and therefore should be used with care in patients with gout or a history of gout.
Keep out of sight and reach of children. Should be used with caution in elderly patients who are more prone to adverse events. The concomitant use of aspirin with other systemic NSAIDs, including cyclooxygenase-2 selective inhibitors, should be avoided due to the potential for additive undesirable effects (see Interactions).
, coffee, tea and some canned drinks) should be avoided while taking this product. g. chronic alcoholism) who were treated with paracetamol at therapeutic dose for a prolonged period or a combination of paracetamol and flucloxacillin.
If HAGMA due to pyroglutamic acidosis is suspected, prompt discontinuation of paracetamol and close monitoringis recommended. The measurement of urinary 5-oxoproline may be useful to identify pyroglutamic acidosis as underlying cause of HAGMA in patients with multiple risk factors.
This medicine contains aspartame (a source of phenylalanine), which may be harmful for people with phenylketonuria (PKU). Patients with rare hereditary problems of galactose intolerance; the Lapp lactose deficiency or glucose-galactose malabsorption should be advised not to take this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially "sodium free".